QbD:Regulatory and Scientific Possibilities and Challenges

Add bookmark

QbD:Regulatory and Scientific Possibilities and Challenges

Add bookmark
Gert Ragnarsson, Director of the Swedish Medical Projects Agency, discusses the biggest milestones in QbD over the last decade, including: The establishment of harmonised guidelines The Formation of the EMA The recent document published by the FDA, which is a significant step in dealing with advanced formulations   He also looks to the future growth of generics and the effects QbD and PAT will have on that market. [inlinead] Ha...

Latest Webinars

Pharma IQ's Power List 2022: In conversation with pharma's top leaders

2022-10-18

02:00 PM - 03:00 PM BST

Join us to hear from the most influential people in pharma today, as voted for by you

A post-pandemic 3D view of the patient and supply journey

2022-06-01

04:30 PM - 05:30 PM CET

In this panel discussion with experts from 4G Clinical, THREAD Research and World Courier, learn how...

Discover how targeted radiotherapy induced toxicity can be identified with imaging

2022-04-28

01:00 PM - 02:00 PM EST

This Pharma IQ webinar with AIQ explores how AI-assisted analysis of radiological scans enhances the...

Recommended